Eugene

[email protected]

LATEST

Novartis Gains Temporary Injunction from Generic Competition of MS Blockbuster Drug Gilenya
By

By
A federal district court judge has ruled in favor of Novartis in granting a temporary injunction barring generic competition for Novartis’ Gilenya (fingolimod hydrochloride), a multiple sclerosis drug. Global product…

Novartis Acquires Takeda’s Dry-Eye Care Drug Xiidra for $5.3 Billion
By

By
Novartis has completed its acquisition of Takeda’s Xiidra (lifitegrast ophthalmic solution), a prescription drug for treating dry eye, in a $5.3-billion deal that includes $3.4 billion upfront and up to…

Lonza To Acquire Sterile Mfg Site from Novartis
By

By
Lonza has entered into a binding contractual agreement for the purchase of a sterile drug-product fill–finish facility in Stein, Switzerland from Novartis. The sterile, multi-product facility currently serves as the…

Pfizer Completes Acquisition of Therachon in $810-Million Deal
By

By
Pfizer has completed its acquisition of Therachon Holding AG, a privately held clinical-stage biotechnology company, in a deal worth up to $810 million. Under the agreement, Pfizer acquired Therachon for…

BMS Completes $1.6-Billion Sale of Consumer Healthcare Business UPSA
By

By
Bristol-Myers Squibb (BMS) has completed its previously announced divestiture of its consumer healthcare business, UPSA, to Taisho Pharmaceutical, an over-the-counter drug company in Japan, for $1.6 billion. BMS had announced…

Former FDA Commissioner Scott Gottlieb Joins Pfizer Board
By

By
Pfizer has announced the election of Scott Gottlieb, MD, the former US Food and Drug Administration (FDA) Commissioner, to its Board of Directors, effective with its announcement on June 27,…

Glenmark Receives Complete Response Letter from FDA for Mfg
By

By
Glenmark Pharmaceuticals, a generics pharmaceutical company, has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding manufacturing issues relating to its new drug application…

Gilead, Carna BioSciences Form $470-Million Immuno-Oncology Pact
By

By
Gilead Sciences and Carna BioSciences, a biopharmaceutical company developing kinase inhibitor drugs for oncology, autoimmune, and neurological diseases, have entered into a research and development collaboration to develop and commercialize…

Akorn Receives FDA Warning Letter
By

By
Akorn, a specialty generic pharmaceutical company, has received a Warning Letter from the US Food and Drug Administration (FDA) related to an inspection by the FDA of its Somerset, New…

Seqens, Ampac, WuXi Biologics and Catalent Expand
By

By
The latest news from CDMOs, CMOs, and suppliers featuring news from Seqens, Ampac, WuXi, and Catalent. Chemicals/Chemical API Manufacturing Seqens to Open New Innovation and Development Center Seqens, a contract development…